GLASGOW, Scotland, UK, June 19, 2014 / B3C newswire / – BioOutsource Ltd. (“BioOutsource”), a leading international Contract Testing Organisation (CTO) today announced their partnership with PsiOxus Therapeutics Ltd. to support clinical sample analysis of their Phase I/II OCTAVE (Ovarian Cancer) study.
PsiOxus Therapeutics, Ltd., an Oxford, based biotechnology company, has been awarded a £1.7 million grant towards a Phase I/II clinical trial to assess the use of Enadenotucirev (previously known as ColoAd1) in the treatment of platinum-resistant, recurrent ovarian cancer. The funding is from the UK government-backed Biomedical Catalyst, a programme run jointly by the Technology Strategy Board and the Medical Research Council. The OCTAVE (Ovarian Cancer Treated with Adeno Vaccine Enadenotucirev) study will be the second clinical trial of the oncolytic vaccine Enadenotucirev, a highly potent, broad-spectrum, anticancer therapeutic capable of destroying tumour cells at very low concentrations.
The OCTAVE Phase I/II study will assess the safety and efficacy of Enadenotucirev when given to patients by intra-peritoneal perfusion at multiple UK cancer centres beginning in June 2014. The Principal Investigator of the OCTAVE study will be Professor Iain McNeish from the Institute of Cancer Sciences at the University of Glasgow. Clinical sample analysis will take place at BioOutsource Ltd, Glasgow, based in the West of Scotland Science Park.
BioOutsource CEO Gerry Mackay commented “BioOutsource are delighted to collaborate with such an innovative biotechnology company as Psioxus Therapeutics and we look forward to continuing to provide ongoing analytical support to assess the efficacy of Enadenotucirev in clinical trials.”
About BioOutsource Ltd
BioOutsource provides contract testing services to the biopharmaceutical industry. Our core offering includes a comprehensive range of services to support the testing of Biologics, Vaccines & BioSimilars throughout their development. We possess an unparalleled combination of commercial, regulatory and technical knowledge that enables us to truly stand out as the industry’s increasingly preferred testing partner. We understand the importance of our service to support our client’s critical testing requirements and as a result, continually strive to provide a world class service globally.
Contacts
Gemma Fulton
Sales & Marketing Department
BioOutsource, Ltd.
+ 44 (0) 141 946 4222
gfulton@biooutsource.com
Help employers find you! Check out all the jobs and post your resume.
